Updated ADS Living Clinical Guideline on MAFLD in People with Diabetes

The Australian Diabetes Society (ADS) has made important updates to the ADS MAFLD living clinical guideline with respect to the Fib-4 calculation and the approval of medications by the FDA.

Download the updated ADS Clinical Care Consensus Living Guideline for Specialist Assessment, Referral and Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease in People with Diabetes (September 2025) – PDF

Updated Australian Obesity Management Algorithm

The Australian Diabetes Society has updated the Australian Obesity Management Algorithm position statement to indicate that tirzepatide (Mounjaro) is TGA approved for the treatment of obesity.

Download the updated Australian Obesity Management Algorithm Position Statement (September 2025) – PDF